<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365285</url>
  </required_header>
  <id_info>
    <org_study_id>141552</org_study_id>
    <nct_id>NCT02365285</nct_id>
  </id_info>
  <brief_title>Racial Differences in Vagal Control of Glucose Homeostasis</brief_title>
  <acronym>RDVCGH</acronym>
  <official_title>Racial Differences in Vagal Control of Glucose Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the hypothesis that acute central acetylcholinesterase inhibition
      will restore PNS activity and reduce oxidation in AAW compared to whites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity has a greater detrimental impact on the health of African American women (AAW) than
      on any other racial or gender group. Nearly 80% of AAW are overweight or obese. Reduced
      insulin sensitivity is more prevalent among AAW as compared to white women and men of both
      races. This condition puts AAW at increased risk for the development of type 2 diabetes
      mellitus. The exact mechanism underlying these pathophysiological differences remains
      unknown. The investigators have found that obese AAW have decreased parasympathetic nerve
      (PNS) activity compared to whites and recent studies in animal models showed that the PNS
      confers protection against oxidative stress. In our AA cohort, PNS activity was directly
      correlated with insulin sensitivity in obese AAW even after controlling for differences in
      age, blood pressure and visceral adiposity. Equally important, the investigators also showed
      that the decrease in insulin sensitivity was associated with increased oxidative stress as
      measured by plasma levels of F2-isoprostanes. Taken together these findings lead us to
      hypothesize that the decreased PNS activity in obese AAW compared to white women has
      deleterious effects on oxidative stress and insulin sensitivity.The investigators will test
      the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity
      and reduce oxidation in AAW compared to whites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">October 5, 2017</completion_date>
  <primary_completion_date type="Actual">October 5, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Oxidative Stress: Baseline to 2 Hours</measure>
    <time_frame>Baseline to 2 hours</time_frame>
    <description>Measure F-2 isoprostanes as a marker of oxidation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oxidative Stress: Baseline to 4 Hours</measure>
    <time_frame>Baseline to 4 hours</time_frame>
    <description>Measure F-2 isoprostanes as a marker of oxidation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Galantamine 16 mg then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galantamine 16 mg po one time dose then placebo on 2nd visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Galantamine 16 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>16 mg po prior to the infusion of intralipid</description>
    <arm_group_label>Galantamine 16 mg then placebo</arm_group_label>
    <arm_group_label>Placebo then Galantamine 16 mg</arm_group_label>
    <other_name>Razadyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Placebo oral capsule prior to the infusion of intralipid/heparin</description>
    <arm_group_label>Galantamine 16 mg then placebo</arm_group_label>
    <arm_group_label>Placebo then Galantamine 16 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine</description>
    <arm_group_label>Galantamine 16 mg then placebo</arm_group_label>
    <arm_group_label>Placebo then Galantamine 16 mg</arm_group_label>
    <other_name>I.V. Fat Emulsion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
    <arm_group_label>Galantamine 16 mg then placebo</arm_group_label>
    <arm_group_label>Placebo then Galantamine 16 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  African American or white (race will be self-defined, but only subjects who report
             both parents of the same race will be included)

          -  18-60 years old

          -  BMI 30-45 Kg/m2

          -  Not pregnant or breastfeeding

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38

          -  Cardiovascular disease such as myocardial infarction within 6 months prior to
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart
             failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral
             valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy.

          -  Arrhythmia (first-, second-, and third-degree atrioventricular (AV) block)

          -  Significant weight change &gt;5% in the past 3 months

          -  Impaired hepatic function (AST and/or Alanine transaminase (ALT) &gt; one and one half
             times (1.5X) upper limit of normal range)

          -  Impaired renal function (eGFR &lt;60ml/min)

          -  Users of strong inhibitors of Cytochrome P450 3A4 (CYP3A4) or cytochrome P450, family
             2, subfamily D, polypeptide 6 (CYP2D6)

          -  Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol

          -  History of alcohol or drug abuse

          -  Mental conditions rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

          -  Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyndya Shibao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center, Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <results_first_submitted>January 16, 2019</results_first_submitted>
  <results_first_submitted_qc>February 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2019</results_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Cyndya Shibao</investigator_full_name>
    <investigator_title>Medical Doctor, Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Galantamine</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02365285/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>52 participants were screen failures and did not receive an intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Galantamine 16 mg Then Placebo (African-American)</title>
          <description>Galantamine 16 mg po one time dose then placebo on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="P2">
          <title>Galantamine 16 mg Then Placebo (White)</title>
          <description>Galantamine 16 mg po one time dose then placebo on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Galantamine 16 mg (African-American)</title>
          <description>Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="P4">
          <title>Placebo Then Galantamine 16 mg (White)</title>
          <description>Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Galantamine 16 mg Then Placebo (African-American)</title>
          <description>Galantamine 16 mg po one time dose then placebo on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="B2">
          <title>Galantamine 16 mg Then Placebo (White)</title>
          <description>Galantamine 16 mg po one time dose then placebo on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="B3">
          <title>Placebo Then Galantamine 16 mg (African-American)</title>
          <description>Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="B4">
          <title>Placebo Then Galantamine 16 mg (White)</title>
          <description>Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Oxidative Stress: Baseline to 2 Hours</title>
        <description>Measure F-2 isoprostanes as a marker of oxidation</description>
        <time_frame>Baseline to 2 hours</time_frame>
        <population>2 white participants dropped out due to nausea. 1 African-American was withdrawn, MD decision.</population>
        <group_list>
          <group group_id="O1">
            <title>Galantamine 16 mg (African-American)</title>
            <description>Galantamine 16 mg po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
          <group group_id="O2">
            <title>Galantamine 16 mg (White)</title>
            <description>Galantamine 16 mg po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (African-American)</title>
            <description>Placebo capsule po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
          <group group_id="O4">
            <title>Placebo (White)</title>
            <description>Placebo capsule po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxidative Stress: Baseline to 2 Hours</title>
          <description>Measure F-2 isoprostanes as a marker of oxidation</description>
          <population>2 white participants dropped out due to nausea. 1 African-American was withdrawn, MD decision.</population>
          <units>pg /ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.012"/>
                    <measurement group_id="O2" value="-0.006" spread="0.018"/>
                    <measurement group_id="O3" value="0.01" spread="0.018"/>
                    <measurement group_id="O4" value="-0.006" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Oxidative Stress: Baseline to 4 Hours</title>
        <description>Measure F-2 isoprostanes as a marker of oxidation</description>
        <time_frame>Baseline to 4 hours</time_frame>
        <population>1 white participant did not have 4 hour F-2 isoprostanes drawn after receiving placebo. 2 white participants dropped out due to nausea. 1 African-American was withdrawn, MD decision.</population>
        <group_list>
          <group group_id="O1">
            <title>Galantamine 16 mg (African-American)</title>
            <description>Galantamine 16 mg po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
          <group group_id="O2">
            <title>Galantamine 16 mg(White)</title>
            <description>Galantamine 16 mg po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
          <group group_id="O3">
            <title>Placebo (African-American)</title>
            <description>Placebo capsule po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
          <group group_id="O4">
            <title>Placebo(White)</title>
            <description>Placebo capsule po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxidative Stress: Baseline to 4 Hours</title>
          <description>Measure F-2 isoprostanes as a marker of oxidation</description>
          <population>1 white participant did not have 4 hour F-2 isoprostanes drawn after receiving placebo. 2 white participants dropped out due to nausea. 1 African-American was withdrawn, MD decision.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.016"/>
                    <measurement group_id="O2" value="-0.008" spread="0.014"/>
                    <measurement group_id="O3" value="0.003" spread="0.005"/>
                    <measurement group_id="O4" value="-0.008" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 2nd study day, usually about 1 month.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Galantamine 16 mg (African-American)</title>
          <description>Galantamine 16 mg po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="E2">
          <title>Galantamine 16 mg (White)</title>
          <description>Galantamine 16 mg po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="E3">
          <title>Placebo (African-American)</title>
          <description>Placebo capsule po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
        <group group_id="E4">
          <title>Placebo (White)</title>
          <description>Placebo capsule po one time dose
Intralipid: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparin: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cyndya Shibao, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-322-2318</phone>
      <email>cyndya.shibao@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

